Literature DB >> 19523965

Does schizophrenia arise from oxidative dysregulation of parvalbumin-interneurons in the developing cortex?

M Margarita Behrens1, Terrence J Sejnowski.   

Abstract

An imbalance in the redox-state of the brain may be part of the underlying pathophysiology in schizophrenia. Inflammatory mediators, such as IL-6, which can tip the redox balance into a pro-oxidant state, have been consistently found to be altered in schizophrenia patients. However, the relationship of altered redox-state to altered brain functions observed in the disease has been unclear. Recent data from a pharmacological model of schizophrenia suggest that redox and inflammatory imbalances may be directly linked to the pathophysiology of the disease by alterations in fast-spiking interneurons. Repetitive adult exposure to the NMDA-R antagonist ketamine increases the levels of the proinflammatory cytokine interleukin-6 in brain which, through activation of the superoxide-producing enzyme NADPH oxidase (Nox2), leads to the loss of the GABAergic phenotype of PV-interneurons and to decreased inhibitory activity in prefrontal cortex. This effect is not observed after a single exposure to ketamine, suggesting that the first exposure to the NMDA-R antagonist primes the brain such that deleterious effects on PV-interneurons appear upon repetitive exposures. The effects of activation of the IL-6/Nox2 pathway on the PV-interneuronal system are reversible in the adult brain, but permanent in the developing cortex. The slow development of PV-interneurons, although essential for shaping of neuronal circuits during postnatal brain development, increases their vulnerability to deleterious insults that can permanently affect their maturational process. Thus, in individuals with genetic predisposition, the persistent activation of the IL-6/Nox2 pathway may be an environmental factor that tips the redox balance leading to schizophrenia symptoms in late adolescence and early adulthood.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19523965      PMCID: PMC2739086          DOI: 10.1016/j.neuropharm.2009.06.002

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  120 in total

1.  Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo.

Authors:  K Q Do; A H Trabesinger; M Kirsten-Krüger; C J Lauer; U Dydak; D Hell; F Holsboer; P Boesiger; M Cuénod
Journal:  Eur J Neurosci       Date:  2000-10       Impact factor: 3.386

Review 2.  Postnatal development of prefrontal inhibitory circuits and the pathophysiology of cognitive dysfunction in schizophrenia.

Authors:  David A Lewis; Dianne Cruz; Stephen Eggan; Susan Erickson
Journal:  Ann N Y Acad Sci       Date:  2004-06       Impact factor: 5.691

3.  NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons.

Authors:  Houman Homayoun; Bita Moghaddam
Journal:  J Neurosci       Date:  2007-10-24       Impact factor: 6.167

4.  GABAergic neuronal subtypes in the human frontal cortex--development and deficits in schizophrenia.

Authors:  G P Reynolds; C L Beasley
Journal:  J Chem Neuroanat       Date:  2001-07       Impact factor: 3.052

5.  Bilateral blockade of NMDA receptors in anterior thalamus by dizocilpine (MK-801) injures pyramidal neurons in rat retrosplenial cortex.

Authors:  S Tomitaka; M Tomitaka; B K Tolliver; F R Sharp
Journal:  Eur J Neurosci       Date:  2000-04       Impact factor: 3.386

6.  The atypical antipsychotic drug clozapine enhances chronic PCP-induced regulation of prefrontal cortex 5-HT2A receptors.

Authors:  Lucinda J Steward; Matthew D Kennedy; Brian J Morris; Judith A Pratt
Journal:  Neuropharmacology       Date:  2004-09       Impact factor: 5.250

7.  Acute and delayed effects of phencyclidine upon mRNA levels of markers of glutamatergic and GABAergic neurotransmitter function in the rat brain.

Authors:  Susan M Cochran; Masatake Fujimura; Brian J Morris; Judith A Pratt
Journal:  Synapse       Date:  2002-12-01       Impact factor: 2.562

8.  The development of neural synchrony reflects late maturation and restructuring of functional networks in humans.

Authors:  Peter J Uhlhaas; Frederic Roux; Wolf Singer; Corinna Haenschel; Ruxandra Sireteanu; Eugenio Rodriguez
Journal:  Proc Natl Acad Sci U S A       Date:  2009-05-28       Impact factor: 11.205

Review 9.  Cysteine regulation of protein function--as exemplified by NMDA-receptor modulation.

Authors:  Stuart A Lipton; Yun-Beom Choi; Hiroto Takahashi; Dongxian Zhang; Weizhong Li; Adam Godzik; Laurie A Bankston
Journal:  Trends Neurosci       Date:  2002-09       Impact factor: 13.837

10.  A loss of parvalbumin-containing interneurons is associated with diminished oscillatory activity in an animal model of schizophrenia.

Authors:  Daniel J Lodge; Margarita M Behrens; Anthony A Grace
Journal:  J Neurosci       Date:  2009-02-25       Impact factor: 6.167

View more
  67 in total

1.  Reduced neuronal inhibition and coordination of adolescent prefrontal cortex during motivated behavior.

Authors:  David A Sturman; Bita Moghaddam
Journal:  J Neurosci       Date:  2011-01-26       Impact factor: 6.167

Review 2.  Targeting NOX enzymes in the central nervous system: therapeutic opportunities.

Authors:  Silvia Sorce; Karl-Heinz Krause; Vincent Jaquet
Journal:  Cell Mol Life Sci       Date:  2012-05-30       Impact factor: 9.261

3.  Deletion of selenoprotein P results in impaired function of parvalbumin interneurons and alterations in fear learning and sensorimotor gating.

Authors:  M W Pitts; A V Raman; A C Hashimoto; C Todorovic; R A Nichols; M J Berry
Journal:  Neuroscience       Date:  2012-02-21       Impact factor: 3.590

Review 4.  Oxidative stress in schizophrenia: an integrated approach.

Authors:  Byron K Y Bitanihirwe; Tsung-Ung W Woo
Journal:  Neurosci Biobehav Rev       Date:  2010-10-23       Impact factor: 8.989

Review 5.  Dysregulation of neural calcium signaling in Alzheimer disease, bipolar disorder and schizophrenia.

Authors:  Michael J Berridge
Journal:  Prion       Date:  2012-08-16       Impact factor: 3.931

6.  Ketamine-induced behavioural and brain oxidative changes in mice: an assessment of possible beneficial effects of zinc as mono- or adjunct therapy.

Authors:  Olakunle James Onaolapo; Olayemi Quyyom Ademakinwa; Temitayo Opeyemi Olalekan; Adejoke Yetunde Onaolapo
Journal:  Psychopharmacology (Berl)       Date:  2017-06-14       Impact factor: 4.530

7.  Prenatal maternal immune disruption and sex-dependent risk for psychoses.

Authors:  J M Goldstein; S Cherkerzian; L J Seidman; J-A L Donatelli; A G Remington; M T Tsuang; M Hornig; S L Buka
Journal:  Psychol Med       Date:  2014-03-26       Impact factor: 7.723

8.  Juvenile exposure to ketamine causes delayed emergence of EEG abnormalities during adulthood in mice.

Authors:  R E Featherstone; L R Nagy; C G Hahn; S J Siegel
Journal:  Drug Alcohol Depend       Date:  2013-09-27       Impact factor: 4.492

9.  Intermittent Hypoxia-Induced Parvalbumin-Immunoreactive Interneurons Loss and Neurobehavioral Impairment is Mediated by NADPH-Oxidase-2.

Authors:  Liang Yuan; Jing Wu; Jiang Liu; Guowei Li; Dong Liang
Journal:  Neurochem Res       Date:  2015-04-25       Impact factor: 3.996

Review 10.  Auditory dysfunction in schizophrenia: integrating clinical and basic features.

Authors:  Daniel C Javitt; Robert A Sweet
Journal:  Nat Rev Neurosci       Date:  2015-09       Impact factor: 34.870

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.